Lisheng Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to shareholders of 78.33 million yuan, down 77.2 percent year on year. Operating revenue was 642 million yuan, down 12.3 percent. Net profit attributable to shareholders after deducting non-recurring items was 67.04 million yuan, down 35.7 percent. Net operating cash flow was negative 44.19 million yuan, down 163.3 percent. Second-quarter net profit attributable to shareholders was 26.44 million yuan, down 90.8 percent year on year. The company said volume-based procurement, consistency evaluation and other policy developments, as well as research and innovation risks and rising production factor costs, have brought multiple challenges to operations. Lisheng Pharmaceutical's share price has fallen 13 percent this year, closing at 15.10 yuan per share on August 20, with a market value of 4.655 billion yuan.
Tianjin Lisheng Pharmaceutical Co LtdFirst-half net profit plunged 77.2% year on year, with revenue down 12.3% and negative operating cash flow.
